TP 0591816
Alternative Names: TP-0591816Latest Information Update: 28 Jul 2024
At a glance
- Originator Taisho Pharmaceutical
- Class Antivirals; Pyrazoles; Pyrimidines
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in Japan
- 22 Jun 2020 Preclinical trials in Respiratory syncytial virus infections in Japan (unspecified route) before June 2020
- 22 Jun 2020 Pharmacodynamics data from preclinical studies in Respiratory syncytial virus presented at the ASM Microbe (ASMM-2020)